(Q53987784)

23 May 2018

title

Variation of ER status between primary and metastatic breast cancer and relationship to p53 expression*. (English)

1 reference

23 May 2018

main subject

metastatic breast cancer

1 reference

Zheng WQ

1

1 reference

23 May 2018

Lu J

2

1 reference

23 May 2018

Zheng JM

3

1 reference

23 May 2018

Hu FX

4

1 reference

23 May 2018

Ni CR

5

1 reference

23 May 2018

publication date

1 December 2001

1 reference

23 May 2018

published in

Steroids

1 reference

23 May 2018

volume

66

1 reference

23 May 2018

page(s)

905-910

1 reference

23 May 2018

issue

12

1 reference

23 May 2018

Estrogen receptors (ER) in human breast cancer. The significance of a new prognostic factor based on both ER protein and ER mRNA contents

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2801%2900121-0

7 January 2021

The relationship between hormone receptor content and the effect of adjuvant tamoxifen in operable breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2801%2900121-0

7 January 2021

Endocrine resistance in advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2801%2900121-0

7 January 2021

Role of estrogen receptor variants in the development of hormone resistance in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2801%2900121-0

7 January 2021

Comparison of Estrogen Receptor Levels in Primary and Regional Metastatic Carcinoma of the Breast

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2801%2900121-0

7 January 2021

The p53 tumour suppressor gene

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2801%2900121-0

7 January 2021

Immunohistochemical detection of p53 protein in mammary carcinoma: an important new independent indicator of prognosis?

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2801%2900121-0

7 January 2021

p53 immunoreactivity in inflammatory and neoplastic diseases of the uterine cervix.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2801%2900121-0

7 January 2021

p53 protein accumulation predicts poor response to tamoxifen therapy of patients with recurrent breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2801%2900121-0

7 January 2021

Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2801%2900121-0

7 January 2021

Estrogen receptor: A prognostic factor in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2801%2900121-0

7 January 2021

Changes in multiple or sequential estrogen receptor determinations in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2801%2900121-0

7 January 2021

The p53 proto-oncogene can act as a suppressor of transformation

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2801%2900121-0

7 January 2021

p53 gene mutations and steroid receptor status in breast cancer. Clinicopathologic correlations and prognostic assessment

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2801%2900121-0

7 January 2021

An immunohistochemical study of p53 with correlations to histopathological parameters, c-erbB-2, proliferating cell nuclear antigen, and prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2801%2900121-0

7 January 2021

Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2801%2900121-0

7 January 2021

10.1016/S0039-128X(01)00121-0

Identifiers

DOI

1 reference

23 May 2018

PubMed ID

11711119

1 reference

23 May 2018